Last reviewed · How we verify
long acting tolterodine 4 mg — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
long acting tolterodine 4 mg (long acting tolterodine 4 mg) — Mansoura University.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| long acting tolterodine 4 mg TARGET | long acting tolterodine 4 mg | Mansoura University | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- long acting tolterodine 4 mg CI watch — RSS
- long acting tolterodine 4 mg CI watch — Atom
- long acting tolterodine 4 mg CI watch — JSON
- long acting tolterodine 4 mg alone — RSS
Cite this brief
Drug Landscape (2026). long acting tolterodine 4 mg — Competitive Intelligence Brief. https://druglandscape.com/ci/long-acting-tolterodine-4-mg. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab